AstraZeneca (LON:AZN) Receives Buy Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by Berenberg Bank in a research report issued on Monday, MarketBeat Ratings reports. They currently have a £150 ($197.24) target price on the biopharmaceutical company’s stock. Berenberg Bank’s price target indicates a potential upside of 13.72% from the company’s previous close.

Other research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 ($144.64) target price on shares of AstraZeneca in a report on Tuesday, June 18th. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Thursday, July 25th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, June 4th. Jefferies Financial Group lifted their price target on shares of AstraZeneca from GBX 71 ($0.93) to GBX 74 ($0.97) and gave the stock a “hold” rating in a research report on Tuesday, July 2nd. Finally, Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of £105.53 ($138.77).

AstraZeneca Stock Performance

AZN opened at £131.90 ($173.44) on Monday. The business has a 50 day moving average price of £125.45 and a two-hundred day moving average price of £117.79. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market capitalization of £204.45 billion, a price-to-earnings ratio of 4,227.56, a price-to-earnings-growth ratio of 1.08 and a beta of 0.15. AstraZeneca has a 1-year low of GBX 9,461 ($124.40) and a 1-year high of £133.88 ($176.04).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.